Meier, Ruth
Greve, Gabriele
Zimmer, Dennis
Bresser, Helena
Berberich, Bettina
Langova, Ralitsa
Stomper, Julia http://orcid.org/0000-0002-3858-4385
Rubarth, Anne
Feuerbach, Lars
Lipka, Daniel B. http://orcid.org/0000-0001-5081-7869
Hey, Joschka http://orcid.org/0000-0003-2842-764X
Grüning, Björn
Brors, Benedikt
Duyster, Justus
Plass, Christoph http://orcid.org/0000-0003-2554-3952
Becker, Heiko
Lübbert, Michael http://orcid.org/0000-0003-1186-1650
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 465 992/1 2012, FOR 2674 A05/A09, SPP 1463 (LU 429/8-2) and Project ID 192904750 - CRC 992 Medical Epigenetics, Clinical Trials Program Grant No 01KG0913)
Bundesministerium für Bildung und Forschung (Grant 031 A538A de.NBI-RBC)
Heiko Becker received honoraria from BMS, Pierre Fabre Pharma, Servier, MSD and Novartis.
Michael Lübbert is on the advisory boards of AbbVie, Astex Pharmaceuticals, Janssen and Syros. He received research funding from Janssen and research support (study drug) from Cheplapharm and Janssen.
Article History
Received: 10 February 2022
Revised: 3 July 2022
Accepted: 29 July 2022
First Online: 22 August 2022
Competing interests
: HB received honoraria from BMS, Pierre Fabre Pharma, Servier, MSD and Novartis. ML is on the advisory boards of AbbVie, Astex Pharmaceuticals, Janssen, and Syros. He received research funding from Janssen and research support (study drug) from Cheplapharm and Janssen. The remaining authors declare no conflicts of interest.